SM16, an Orally Active TGF-β Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model | Zendy

Kai Fu | Zendy; Michael J. Corbley | Zendy; Lihong Sun | Zendy; Jessica E. Friedman | Zendy; Feng Shan | Zendy; James L. Papadatos | Zendy; Donald E. Costa | Zendy; Frank Lutterodt | Zendy; Harry Sweigard | Zendy; Scott Bowes | Zendy; Michael Y. Choi | Zendy; P. Ann BoriackSjodin | Zendy; Robert M. Arduini | Zendy; Dongyu Sun | Zendy; Miki Newman | Zendy; Xiamei Zhang | Zendy; Jonathan N. Mead | Zendy; Claudio Chuaqui | Zendy; Hung Kam Cheung | Zendy; Xin Zhang | Zendy; Mark Cornebise | Zendy; Mary Beth Carter | Zendy; Serene Josiah | Zendy; Juswinder Singh | Zendy; WenCherng Lee | Zendy; Alan Gill | Zendy; Leona Ling | Zendy

Open Access

SM16, an Orally Active TGF-β Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Author(s) -

Kai Fu,

Michael J. Corbley,

Lihong Sun,

Jessica E. Friedman,

Feng Shan,

James L. Papadatos,

Donald E. Costa,

Frank Lutterodt,

Harry Sweigard,

Scott Bowes,

Michael Y. Choi,

P. Ann BoriackSjodin,

Robert M. Arduini,

Dongyu Sun,

Miki Newman,

Xiamei Zhang,

Jonathan N. Mead,

Claudio Chuaqui,

Hung Kam Cheung,

Xin Zhang,

Mark Cornebise,

Mary Beth Carter,

Serene Josiah,

Juswinder Singh,

WenCherng Lee,

Alan Gill,

Leona Ling

Publication year - 2008

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.107.158030

Subject(s) - myofibroblast , vascular smooth muscle , fibrosis , plasminogen activator inhibitor 1 , tgf beta signaling pathway , pharmacology , kinase , plasminogen activator , activator (genetics) , chemistry , transforming growth factor beta , transforming growth factor , endoglin , p38 mitogen activated protein kinases , mapk/erk pathway , receptor , medicine , biology , pathology , endocrinology , microbiology and biotechnology , biochemistry , smooth muscle , cd34 , stem cell

Objective— TGF-β plays a significant role in vascular injury-induced stenosis. This study evaluates the efficacy of a novel, small molecule inhibitor of ALK5/ALK4 kinase, in the rat carotid injury model of vascular fibrosis.Methods and Results— The small molecule, SM16, was shown to bind with high affinity to ALK5 kinase ATP binding site using a competitive binding assay and biacore analysis. SM16 blocked TGF-β and activin-induced Smad2/3 phosphorylation and TGF-β-induced plasminogen activator inhibitor (PAI)-luciferase activity in cells. Good overall selectivity was demonstrated in a large panel of kinase assays, but SM16 also showed nanomolar inhibition of ALK4 and weak (micromolar) inhibition of Raf and p38. In the rat carotid injury model, SM16 dosed once daily orally at 15 or 30 mg/kg SM16 for 14 days caused significant inhibition of neointimal thickening and lumenal narrowing. SM16 also prevented induction of adventitial smooth muscle α-actin–positive myofibroblasts and the production of intimal collagen, but did not decrease the percentage of proliferative cells.Conclusion— These results are the first to demonstrate the efficacy of an orally active, small-molecule ALK5/ALK4 inhibitor in a vascular fibrosis model and suggest the potential therapeutic application of these inhibitors in vascular fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research